• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    SC 13G/A 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Perspective Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value

     

    (Title of Class of Securities)

     

    46489V302

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,350,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,350,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,350,000*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.96%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,350,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,350,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,350,000*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.96%*

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    Item 1. (a) Name of Issuer

     

    Perspective Therapeutics, Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    2401 Elliott Avenue, Suite 320, Seattle, Washington 98121

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Stock, $0.001 par value (the “Common Shares”)

     

    Item 2. (e) CUSIP No.:

     

    46489V302

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    Item 4. Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

    (a) Amount Beneficially Owned: 3,350,000*

     

    (b) Percent of Class: 4.96%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 3,350,000*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 3,350,000*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

    (a) Amount Beneficially Owned: 3,350,000*

     

    (b) Percent of Class: 4.96%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 3,350,000*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 3,350,000*

     

    *The Firm is the investment manager to Commodore Master. As of September 30, 2024, the Firm may be deemed to beneficially own an aggregate of 3,350,000 Common Shares of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 67,562,781 Common Shares reported as issued and outstanding as of September 30, 2024 in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2024.

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

      1. Joint Filing Agreement dated as of April 19, 2024, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on April 19, 2024).

     

     

     

     

    CUSIP No. 46489V302 SCHEDULE 13G

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: November 14, 2024
       
      Commodore Capital LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Managing Partner
         
      Commodore Capital Master LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Authorized Signatory

     

     

     

    Get the next $CATX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

    3/13/25 7:26:51 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Scotiabank initiated coverage on Perspective Therapeutics with a new price target

    Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

    3/7/25 8:03:16 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

    11/25/24 7:39:30 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    SEC Filings

    View All

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/4/25 7:04:41 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/3/25 7:04:59 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/2/25 7:00:38 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:04:49 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:03:59 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics to Participate in Upcoming September Conferences

    SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences. Cantor Global Healthcare Conference – Fireside ChatDate: Thursday, September 4, 2025Time: 1:00 p.m. - 1:30 p.m. ETLocation: New York, NY Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: Tuesday, September 9, 2025Location: New York, NY OPCO Targeted Radiopharmaceutical Therapies in Oncology Sum

    8/26/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Sendek Joel

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:06:51 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sendek Joel

    3 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:05:22 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:04:08 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/7/24 9:24:55 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

     Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

    5/30/25 5:21:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

      Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

    1/24/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

    SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

    1/22/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care